Boehringer Ingelheim and Sosei Heptares join forces to
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to ...
Read moreSingle-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to ...
Read moreTokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will ...
Read moreTokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces ...
Read moreTokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides ...
Read moreTokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), ...
Read moreTokyo, Japan and Cambridge, UK, 7 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces ...
Read morePF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.